Erythropoietin Resistance as Surrogate Marker of Graft and Patient Survival in Renal Transplantation: 3-Year Prospective Multicenter Study

Abstract Background Some transplant recipients demonstrate an inadequate response to erythropoiesis-stimulating agents, or so-called erythropoietin (Epo) resistance. The cause is multifactorial. Resistance to EPO may entail a poor prognosis for the graft and the patient, although results in the lite...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2010-10, Vol.42 (8), p.2935-2937
Main Authors: Gomez-Alamillo, C, Fernández-Fresnedo, G, Ortega, F, Campistol, J.M, Gentil, M.A, Arias, M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Drug Resistance
Erythropoietin - pharmacology
Erythropoietin - therapeutic use
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Graft Rejection
Graft Survival
Humans
Kidney Transplantation
Medical sciences
Miscellaneous
Prognosis
Prospective Studies
Public health. Hygiene
Public health. Hygiene-occupational medicine
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the urinary system
Tissue, organ and graft immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Some transplant recipients demonstrate an inadequate response to erythropoiesis-stimulating agents, or so-called erythropoietin (Epo) resistance. The cause is multifactorial. Resistance to EPO may entail a poor prognosis for the graft and the patient, although results in the literature are inconsistent, and long-term follow-up is lacking. Objective To evaluate whether the presence of Epo resistance at the beginning of the study was a predictive factor for graft and patient survival. Materials and Methods From 482 renal transplant recipients (Kidney Disease Outcomes Quality Initiative stage 3–4T) receiving Epo-stimulating agents in the Anemia and Renal Transplantation in Spain study, 101 were selected for the present study. Erythropoietin resistance was defined as a ratio of weekly Epo dosage/hemoglobin concentration >486,94 U/g/dL with a hemoglobin/
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2010.07.043